TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16193338

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Functional + Resistance Training (FRT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Functional Training (FT)
Number of subjects: 24
Study: 12038497

Group type: EXPERIMENTAL
Intervention: 10 hours of timing training with an instrument designed to train participants to tap their hands and feet in synchrony with target sounds.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition involved reading literature about how to improve golf swing.
Number of subjects: 40
Study: 9926181

Group type: EXPERIMENTAL
Intervention: i.v. ketoprofen (1 mg kg-1 followed by an infusion of 1 mg kg-1 over 2 h)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: i.v. ketoprofen
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 59
Study: 7676786

Group type: EXPERIMENTAL
Intervention: 0.1 Hz Single Twitch Stimulation (STS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.1 Hz Single Burst Stimulation (SBS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.05 Hz Single Twitch Stimulation (STS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.05 Hz Single Burst Stimulation (SBS)
Number of subjects: 100
Study: 1693062

Group type: EXPERIMENTAL
Intervention: rG-CSF administered intravenously at a dose of 100 micrograms/m2
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: rG-CSF administered subcutaneously at a dose of 75 micrograms
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: rG-CSF administered subcutaneously at a dose of 100 micrograms/m2
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: rG-CSF administered subcutaneously at a dose of 125 micrograms
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (without rG-CSF)
Number of subjects: 53
Study: 7387806

Group type: EXPERIMENTAL
Intervention: Incremental administration of thiopentone (50‐mg increments every 15 s)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bolus administration of thiopentone (4‐mg kg‐1)
Number of subjects: 20
Study: 31875276

Group type: EXPERIMENTAL
Intervention: Subcutaneous pasireotide 600-μg twice daily
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Subcutaneous pasireotide 900-μg twice daily
Number of subjects: 162
Study: 31125538

Group type: EXPERIMENTAL
Intervention: Anterior technique with 2.7 mL of anesthetic
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Anterior technique with 1.8 mL of anesthetic
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional IANB with 1.8 mL of anesthetic
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional IANB with 2.7 mL of anesthetic
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: MRI analysis of anterior technique
Number of subjects: 108
Study: 27173671

Group type: EXPERIMENTAL
Intervention: Front treatment (targeted product placed in the front)
Number of subjects: 886

Group type: COMPARATOR
Intervention: Back treatment (targeted product placed in the back)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Boxed intervention (targeted product presented in its original box)
Number of subjects: 886

Group type: COMPARATOR
Intervention: Unboxed treatment (targeted product presented unboxed)
Number of subjects: 886
Study: 25884634

Group type: EXPERIMENTAL
Intervention: Baby Triple P for Preterm infants
Number of subjects: 330

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 330
Study: 23981052

Group type: EXPERIMENTAL
Intervention: Early follicular phase (low hormone levels)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Luteal phase (high hormone levels)
Number of subjects: 0
Study: 22234084

Group type: EXPERIMENTAL
Intervention: Endoscopic pancreatic stenting (EPS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (no EPS)
Number of subjects: 41
Study: 19618262

Group type: EXPERIMENTAL
Intervention: EMG‐biofeedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition (information about bowel functioning and counseling)
Number of subjects: 30
Study: 17901096

Group type: EXPERIMENTAL
Intervention: Various assessment tools for measuring emesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific and global assessment tools
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily clinical assessment, prevalence surveys, randomized controlled trial settings
Number of subjects: 0
Study: 12447512

Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg daily
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 10512345

Group type: EXPERIMENTAL
Intervention: Clotrimazole 1% cream applied twice daily for 3 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fluconazole 200 mg once weekly for 3 weeks
Number of subjects: 22
Study: 8835618

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 23 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (both doses)
Number of subjects: 30
Study: 2201165

Group type: EXPERIMENTAL
Intervention: GGG‐ORS
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard ORS
Number of subjects: 92
Study: 6892984

Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy
Number of subjects: 198
Study: 30038044

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Both TAF and TDF
Number of subjects: 1298
Study: 28963118

Group type: EXPERIMENTAL
Intervention: B cell depletion
Number of subjects: 0
Study: 26481741

Group type: EXPERIMENTAL
Intervention: Early postsurgical temozolomide (TMZ) plus standard concomitant radiochemotherapy regimen
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard concomitant radiochemotherapy regimen
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Early postsurgical temozolomide (TMZ)
Number of subjects: 99
Study: 23666915

Group type: EXPERIMENTAL
Intervention: Ipilimumab at 0.3 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipilimumab at 3 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipilimumab at 10 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipilimumab at 10 mg/kg (treatment-naïve patients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipilimumab at 10 mg/kg (retreatment upon disease progression)
Number of subjects: 0
Study: 22030767

Group type: EXPERIMENTAL
Intervention: Reflective Adaptive Process (RAP), a 12-week intensive QI process
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Engagement of residents in the QI process
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Larger practices with resources and characteristics supporting QI
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Developmental approach to QI for smaller practices
Number of subjects: 7
Study: 18469239

Group type: EXPERIMENTAL
Intervention: HFCS
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fructose
Number of subjects: 34

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 34
Study: 17034372

Group type: EXPERIMENTAL
Intervention: Eflornithine cream
Number of subjects: 54

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Combination therapy (Eflornithine + laser)
Number of subjects: 54
Study: 14617299

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 85
Study: 9989685

Group type: EXPERIMENTAL
Intervention: Red yeast rice (2.4 g/d)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 7750388

Group type: EXPERIMENTAL
Intervention: On demand ultrasound
Number of subjects: 308

Group type: COMPARATOR
Intervention: Routine ultrasound
Number of subjects: 308
Study: 2249116

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 119975

Group type: EXPERIMENTAL
Intervention: Thiamphenicol
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Cephazolin
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Thiamphenicol plus Cephazolin
Number of subjects: 420

Group type: COMPARATOR
Intervention: Local nitrofurantoin treatment
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Local treatment of the vagina
Number of subjects: 420
Study: 30199448

Group type: EXPERIMENTAL
Intervention: Barbell velocity during the bench press (BP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Weight velocity during the 2 leg press (2LP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Machine-based exercise
Number of subjects: 40
Study: 30777368

Group type: EXPERIMENTAL
Intervention: C-MAC
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: King Vision®
Number of subjects: 180

Group type: COMPARATOR
Intervention: Direct Laryngoscopy
Number of subjects: 180
Study: 29208752

Group type: EXPERIMENTAL
Intervention: Alanyl-Glutamine (AlaGln) supplemented PD fluid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard PD fluid
Number of subjects: 20
Study: 26999113

Group type: EXPERIMENTAL
Intervention: Citicoline treatment
Number of subjects: 163

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 163
Study: 25675664

Group type: EXPERIMENTAL
Intervention: Levobupivacaine infiltration (5 ml, 50 mg/10 ml)
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0.9% sodium chloride infiltration
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Levobupivacaine infiltration
Number of subjects: 44
Study: 22436595

Group type: EXPERIMENTAL
Intervention: Psycho-educational and cognitive behavioural stabilizing group treatment (experimental treatment; EXP) added to treatment as usual (TAU)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 29
Study: 20630920

Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 4% gelatine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4 and 4% gelatine
Number of subjects: 45
Study: 17990133

Group type: EXPERIMENTAL
Intervention: Shared-decision making
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Preference for shared-decision making
Number of subjects: 636
Study: 15866397

Group type: EXPERIMENTAL
Intervention: Ibuprofen 5% cream
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 55
Study: 11935040

Group type: EXPERIMENTAL
Intervention: Increased serum immune complexes (IC) concentration in stroke patients
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Presence of Chlamydia pneumoniae antigen in IC
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Presence of anti-CMV antibodies in IC
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Neurological status and 30-day mortality rate
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control groups (old and young)
Number of subjects: 179
Study: 9479343

Group type: EXPERIMENTAL
Intervention: AutoPap System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current practice
Number of subjects: 0
Study: 7872228

Group type: EXPERIMENTAL
Intervention: 6 g n-3 FAs/d for 6 weeks followed by 3 g/d for 12 weeks
Number of subjects: 0
Study: 29677641

Group type: EXPERIMENTAL
Intervention: UFT (oral tegafur-uracil) at 500-600 mg/day for 5 days followed by 2-day rest for 1 year
Number of subjects: 1982

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1982

Group type: EXPERIMENTAL
Intervention: UFT (oral tegafur-uracil)
Number of subjects: 1982
Study: 28731602

Group type: EXPERIMENTAL
Intervention: Remer and Manz equation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Frassetto et al. equation one
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Frassetto et al. equation two
Number of subjects: 13
Study: 26284393

Group type: EXPERIMENTAL
Intervention: 'Sandwich' urethra reconstruction
Number of subjects: 71

Group type: COMPARATOR
Intervention: No reconstruction (Control)
Number of subjects: 71
Study: 24002280

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) with iron (12.5 mg/d of iron)
Number of subjects: 1958

Group type: COMPARATOR
Intervention: Micronutrient powder (MNP) without iron
Number of subjects: 1958
Study: 21235310

Group type: EXPERIMENTAL
Intervention: Open shunts
Number of subjects: 14

Group type: COMPARATOR
Intervention: Closed shunts (initially ligated)
Number of subjects: 14
Study: 19026262

Group type: EXPERIMENTAL
Intervention: Panic‐Focused Psychodynamic Therapy (PFPP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Applied Relaxation Therapy (ART)
Number of subjects: 49
Study: 16765144

Group type: EXPERIMENTAL
Intervention: Palifermin 60 mug/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palifermin 120 mug/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palifermin 250 mug/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15607390

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (Taxus)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 48
Study: 11265777

Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 9236434

Group type: EXPERIMENTAL
Intervention: RheothRx (poloxamer 188)
Number of subjects: 2948
Study: 7955819

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion (0.0025 to 0.01 micrograms/kg/min) with ganglionic blockade (trimethaphan) in young subjects
Number of subjects: 29

Group type: COMPARATOR
Intervention: Isoproterenol infusion (0.005 to 0.03 micrograms/kg/min) without ganglionic blockade
Number of subjects: 29

Group type: COMPARATOR
Intervention: Isoproterenol infusion
Number of subjects: 29
Study: 3612344

Group type: EXPERIMENTAL
Intervention: Intervention group (mailings of information, appointment reminders, intense follow-up by telephone)
Number of subjects: 854

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 854
Study: 31855875

Group type: EXPERIMENTAL
Intervention: NCRT plus surgery (S)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: NCRT
Number of subjects: 389
Study: 31764068

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 2394

Group type: COMPARATOR
Intervention: Placebo vaginal ring
Number of subjects: 2394

Group type: COMPARATOR
Intervention: Oral placebo arm of VOICE trial
Number of subjects: 2394
Study: 29933006

Group type: EXPERIMENTAL
Intervention: Scotchbond Universal™ (SBU, 3 M) with self‐etch (SE)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Scotchbond Universal™ (SBU, 3 M) with etch-and-rinse (ER)
Number of subjects: 22

Group type: COMPARATOR
Intervention: OptiBond™ FL (OFL, Kerr)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Scotchbond Universal™ (SBU, 3 M) with selective‐enamel‐etch (SEE)
Number of subjects: 22
Study: 26420732

Group type: EXPERIMENTAL
Intervention: 5-year multi-intervention programme including physical activity, diet, and general health education.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (Pune controls).
Number of subjects: 3
Study: 24954607

Group type: EXPERIMENTAL
Intervention: Ethanol injection
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sodium tetradecyl sulfate (STS) injection
Number of subjects: 47
Study: 22252206

Group type: EXPERIMENTAL
Intervention: Pentavalent human-bovine reassortant rotavirus vaccine (PRV)
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1003
Study: 19945804

Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI)
Number of subjects: 2876
Study: 18300064

Group type: EXPERIMENTAL
Intervention: Incremental risk framing
Number of subjects: 2405

Group type: EXPERIMENTAL
Intervention: Sequential presentation of risks
Number of subjects: 2405

Group type: COMPARATOR
Intervention: Total risk presentation
Number of subjects: 2405
Study: 15911729

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg once a day)
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1470

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 1470
Study: 12896934

Group type: EXPERIMENTAL
Intervention: Active treatment: two injections of enzyme potentiated desensitisation, each comprising 200 Fishman units of beta glucuronidase, 50 pg 1,3‐cyclohexanediol, 50 ng protamine sulphate, and a mixed inhaled allergen extract in a total volume of 0.05 ml of buffered saline.
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo: two injections of 0.05 ml buffered saline solution.
Number of subjects: 183
Study: 10475418

Group type: EXPERIMENTAL
Intervention: Off-pump coronary revascularization
Number of subjects: 50

Group type: COMPARATOR
Intervention: On-pump coronary revascularization
Number of subjects: 50
Study: 8941526

Group type: EXPERIMENTAL
Intervention: Swimming and resistance training combined (SR)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Resistance training workout (RW)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Intense interval swimming (SW)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 7
Study: 1832920

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.15 mg kg-1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg kg-1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg kg-1 over 30 s
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mivacurium infusion at 8-10 micrograms kg-1 min-1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.04 mg kg-1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.75 mg kg-1
Number of subjects: 45

Group type: COMPARATOR
Intervention: Spontaneous recovery
Number of subjects: 45
Study: 6645210

Group type: EXPERIMENTAL
Intervention: Hypocalcemia induced during hemodialysis by employing a dialysate devoid of calcium
Number of subjects: 0
Study: 30815897

Group type: EXPERIMENTAL
Intervention: Chondrogenic‐induced mesenchymal stem cells + equine allogeneic plasma
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 12
Study: 27864024

Group type: EXPERIMENTAL
Intervention: SQ HDM SLIT tablet (10,000 JAU)
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: SQ HDM SLIT tablet (20,000 JAU)
Number of subjects: 946

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: SQ HDM SLIT tablet
Number of subjects: 946
Study: 26850270

Group type: EXPERIMENTAL
Intervention: Oral tenofovir (TFV)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Vaginal tenofovir (TFV)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Behavioural measures (FTFI, ACASI, PC)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Behavioural measures
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Oral group correlates
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Vaginal group correlates
Number of subjects: 472
Study: 25148718

Group type: EXPERIMENTAL
Intervention: Ambu AuraOnce™
Number of subjects: 178

Group type: COMPARATOR
Intervention: LMA-Unique™
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: I-Gel™
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: LMA-Suprême™
Number of subjects: 178
Study: 22361251

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (50,000 IU) given orally once on the day of birth or within the next two days
Number of subjects: 104200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104200
Study: 20647390

Group type: EXPERIMENTAL
Intervention: Oral lactoferrin (200 mg/day)
Number of subjects: 148

Group type: COMPARATOR
Intervention: i.v. iron (125 mg weekly)
Number of subjects: 148
Study: 17452390

Group type: EXPERIMENTAL
Intervention: Community pharmacist intervention (two home visits within two to eight weeks of discharge, drug review, symptom self-management, and lifestyle advice)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 293
Study: 15476202

Group type: EXPERIMENTAL
Intervention: Folinic acid supplementation during MTX therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Folic acid supplementation during MTX therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Folinic acid supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Folic acid supplementation
Number of subjects: 40
Study: 11535323

Group type: EXPERIMENTAL
Intervention: VAQTA 50-U at 6 months (Group I)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: VAQTA 50-U at 12 months (Group II)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: VAQTA 50-U at 18 months (Group III)
Number of subjects: 283
Study: 9505927

Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg twice daily (n = 19)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg daily (n = 21)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 50
Study: 7838448

Group type: EXPERIMENTAL
Intervention: Acute experimental ischaemia
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pumping in experimental infarction
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of sodium nitroprusside in experimental infarction
Number of subjects: 58

Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 58

Group type: COMPARATOR
Intervention: Post-myocardial infarction patients
Number of subjects: 58
Study: 3254728

Group type: EXPERIMENTAL
Intervention: Resting quietly
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Reading neutral entertaining material (Herman cartoons)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Reading stress-relevant questionnaires
Number of subjects: 115
Study: 31767543

Group type: EXPERIMENTAL
Intervention: Deep learning algorithm for histopathologic diagnosis and Gleason grading
Number of subjects: 25
Study: 31820546

Group type: EXPERIMENTAL
Intervention: Vericiguat (soluble guanylate cyclase stimulator)
Number of subjects: 5050

Group type: COMPARATOR
Intervention: Standard heart failure care (triple therapy)
Number of subjects: 5050

Group type: COMPARATOR
Intervention: PARADIGM-HF
Number of subjects: 5050
Study: 28621326

Group type: EXPERIMENTAL
Intervention: Resin infiltrant combined with flowable composite resin (RI/CR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flowable composite resin (CR)
Number of subjects: 40